First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback